Welcome to our website. Here you will find information about our current portfolio of trials.
We have a varied portfolio of trials within the division (including Child and Maternal health, Endocrinology / diabetes, Rheumatology) Including both CTIMP and non-CTIMP (e.g., device) interventions for patients within the national health services. These are typically large multicentre trials, involving many hospitals and trusts both nationally and sometimes internationally.
The LCTU is part of the Liverpool Trials Collaborative which is one of 46 UKCRC Registered Clinical Trials Units. The unit receives National Institute for Health Research CTU Support Funding which has been awarded to support the unit in developing and supporting NIHR trials.
New approach improves five-year survival for pancreatic cancer patients
A University of Liverpool led clinical trial has shown that 29% of pancreatic cancer patients given a combination of two chemotherapy drugs lived for at least five years compared with 16% who received the one chemotherapy drug.
The latest Cancer Research UK figures show that around 9,400 people are diagnosed with pancreatic cancer each year in the UK and around 8,800 people die from the disease each year.
The trial involved 732 patients in hospitals across the UK, German, Sweden .....
Liverpool Scientists Set To Get Million Pound Cash Boost For Cancer Research
LIVERPOOL scientists and doctors are set to receive a major cash boost for research into cancer.
Leading research charity Cancer Research UK and the National Institute for Health Research (NIHR) plan to invest nearly £1.5m over the next five years into ground-breaking work at the Liverpool Experimental Cancer Medicine Centre (ECMC)*.
In Liverpool, the ECMC is a collaboration between The Clatterbridge Cancer Centre NHS Foundation Trust, the Cancer Research UK Liverpool .....
Launch of SAVER, an NIHR EME funded oral cancer prevention study
Professor Richard Shaw’s NIHR EME funded Sodium Valproate for the Epigenetic Reprogramming of High-Risk Oral Epithelial Dysplasia (SAVER) trial, investigating the role of Sodium Valproate in chemoprevention of Oral Squamous Cell Carcinoma (OSCC), had a very successful launch event on 29th November ’16. The day also provided a clinical update opportunity for the management of Oral Epithelial Dysplasis (OED). Presentation topics included the management of OED, Allelic Imbalance and .....
£226 million UK investment in cancer research announced
Cancer Research UK has announced the largest investment to date into its network of Centres across the UK. £190 million has been committed to 13 Cancer Research UK Centres over the next five years. The huge investment will draw together world class research and medical expertise to accelerate advances in research and support clinical trials essential to getting lifesaving treatments to patients.
Sorry there are currently no job vacancies